Related Experiment Video
Updated: Aug 14, 2026
07:31
Nitropeptide Profiling and Identification Illustrated by Angiotensin II
Published on: June 16, 2019
Natriuretic peptides and their therapeutic potential
1Department of Medicine, Brown University School of Medicine, Providence, Rhode Island, USA.
Heart Disease (Hagerstown, Md.)
|November 27, 2001
Summary
Natriuretic peptides, including ANP and BNP, oppose the renin-angiotensin system, influencing blood pressure and volume. Elevated levels indicate cardiovascular disease, with therapeutic potential in heart failure and hypertension.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
- Pharmacology
Background:
- Natriuretic peptides (NPs) are endogenous hormones counteracting the renin-angiotensin system.
- Key NPs include atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).
- NPs regulate blood pressure, fluid balance, and aldosterone secretion.
Purpose of the Study:
- To review the physiology and pathophysiology of natriuretic peptides.
- To explore their role as biomarkers in cardiovascular diseases.
- To discuss therapeutic applications of NPs and related drugs.
Main Methods:
- Literature review of natriuretic peptide research.
- Analysis of NP roles in cardiovascular regulation.
- Examination of clinical applications and emerging therapies.
Main Results:
- ANP and BNP induce vasodilation, natriuresis, and reduced intravascular volume.
- CNP primarily exerts hypotensive effects.
- Elevated NP levels are associated with congestive heart failure, hypertension, and myocardial infarction.
- NPs serve as critical diagnostic and prognostic markers.
Conclusions:
- Natriuretic peptides are vital regulators of cardiovascular homeostasis.
- Therapeutic strategies include direct NP administration (e.g., BNP for CHF) and inhibition of NP degradation (e.g., NEP inhibitors).
- Further research into NP pathways holds promise for treating cardiovascular diseases.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...